A novel immunotherapy strategy using in vivo generation of engineered CAR T cells can reduce fibrosis and restore cardiac function in a mouse model of heart failure, researchers report in Science. Read more ⬇ SciencePerspective:
). Thus, CD5/LNP-FAPCAR treatment results in improved function and decreased interstitial fibrosis. We did not observe any gross histological changes in noncardiac organs or weight loss after CD5/LNP-FAPCAR injection .
These experimental results provide a proof of concept that modified mRNA encapsulated in targeted LNPs can be delivered intravenously to produce functional engineered T cells in vivo. The marked success and safety of modified mRNA/LNP severe acute respiratory syndrome coronavirus 2 vaccines has stimulated broad efforts to extend this therapeutic platform to address numerous pathologies.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Deadly car bomb blast rocks Somali capital MogadishuA suicide car bomb blast took place outside the international airport in Somalia’s capital, killing at least 8 people and injuring 5 others.
Lire la suite »
GM launching CarBravo used car marketplaceGeneral Motors is launching a new used car platform called CarBravo that will tap into its dealer network's stock of used cars.
Lire la suite »
Renovated historic home in Dauphin County with 8-car garage, Susquehanna River views: Cool SpacesRenovations to the 4,167 square-foot home in 1990 include an attached six-car garage, gourmet kitchen and large den.
Lire la suite »
Peer-to-peer car-sharing service Turo files to go publicIt opted for a traditional IPO rather than a SPAC.
Lire la suite »
GM Takes Aim at Carvana, Vroom With Used-Car WebsiteThe auto maker’s new CarBravo a marketplace will let U.S. GM dealers sell used cars online, a move that adds new competition to the used-vehicle market and reflects a strategic shift for GM.
Lire la suite »